title: The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment.
abstract: The variation in ABO blood groups is reported to be associated with multiple diseases. Infliximab (IFX) has been widely used in the treatment of Crohn's disease (CD). We aim to investigate the distribution of ABO blood groups in Chinese patients with CD and to explore its impact on response to IFX.
  
  
  
  Patients with CD were consecutively recruited to the study between 2007 and 2014. CD patients receiving IFX therapy were followed for at least two years.
  
  
  
  In 293 patients with CD, most patients (40.6%) had blood type O (119/293). The odds ratio (OR) of CD in blood type O patients was 1.06 (95%CI: 0.6-1.86; p=0.84) compared to all other blood types. Among those CD patients, 107 patients received IFX treatment. One year after the first course of IFX, a significant association was found between the overall ABO system and outcomes of IFX treatment (p<0.001). CD patients with blood type AB (OR=4.42, 95% CI: 1.04-18.76; p=0.044) were more likely to achieve mucosal healing, while CD patients with blood type A had a high risk of losing response (OR=0.38, 95% CI: 0.15-0.96; p=0.040).
  
  
  
  ABO blood groups are not associated with prevalence of CD. Patients with blood type AB had a better response to IFX while those with blood type A appeared to have a risk of losing response to IFX.
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Qiao
authors.initials: Q
authors.lastname: Yu
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Lingyun
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Shenghong
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Feng
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Baili
authors.initials: B
authors.lastname: Chen
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Minhu
authors.initials: M
authors.lastname: Chen
mesh_terms: D000017:ABO Blood-Group System / Q000032:analysis*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D003424:Crohn Disease / Q000097:blood* / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D015995:Prevalence; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000017:ABO Blood-Group System; D005765:Gastrointestinal Agents; D000069285:Infliximab